Additional file 2 of Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study

Additional file 2: Table S1. Risk of incident CVD per two-fold higher sphingolipid level in SHFS. Table S2. Odds of incident CVD per two-fold higher sphingolipid level in SHS. Table S3. Sensitivity analysis—associations of sphingolipids with incident CVD risk after adjustment for HDL and Triglycerides, Fibrinogen, and Chronic Kidney Disease

Comparison of linkage disequilibrium patterns between populations of African and European descent for six previously identified QT loci significantly associated with QT in n = 8,644 African American participants.

a<p>r²≥0.50.</p>b<p>Calculated using African American LD patterns.</p>c<p>Calculated using European LD patterns.</p>d<p>Calculated as (European region size - African American region size (Kb)).</p><p>Kb, kilobase. LD, linkage disequilibrium.</p

−Log <i>P</i> plot for common SNPs at the <i>NOS1AP</i> independent signal 1 and 2 loci.

<p><i>P</i>-values are estimated in African Americans and are plotted using linkage disequilibrium estimates from African Americans (panels A and C) and Europeans (panels B and D). SNPs are represented by <i>circles</i>, lines indicate index SNPS previously identified in GWA studies of European and Indian Asian populations, and the <i>large blue diamond</i> is the best marker in African Americans. Circle color represents correlation with the best marker in African Americans: <i>blue</i> indicates weak correlation and <i>red</i> indicates strong correlation. Recombination rate is plotted in the background and annotated genes are shown at the bottom of the plot.</p

Novel and independent SNPs associated with QT at two previously identified QT loci in n = 8,644 African American participants.

a<p>Restricted to SNPs with minor allele frequency ≥0.01 that passed quality control and defined as locus-specific SNP with the lowest <i>P</i>-value.</p>b<p>Coded allele listed first.</p>c<p>Calculated in the Atherosclerosis Risk in Communities Study.</p>d<p>Calculated in the Malmö Diet and Cancer Study.</p>e<p>Adjusted for rs12061601.</p><p>Est, estimate. SE, standard error. SNP, single nucleotide polymorphism.</p

Associations with common variants at fifteen previously reported QT loci across eleven chromosomes in n = 8,644 African American participants.

a<p>Restricted to SNPs with minor allele frequency ≥0.01.</p>b<p>Calculated in the Malmö Diet and Cancer Study or 1,000 Genomes CEU data when Malmö data unavailable.</p>c<p>Calculated in the Atherosclerosis Risk in Communities Study.</p>d<p>SNP not present on Metabochip, SNP proxy substituted.</p>e<p>SNP not present on Metabochip, but in very high LD with rs2968863 (r²>0.95).</p>f<p>SNP failed quality control and no proxy was available.</p><p>AF, African American. BP, base pair. CAF, coded allele frequency. Est, estimate. EU, European. GWA, genome wide association. Ind, independent. NA, not available. SE, standard error. SNP, single nucleotide polymorphism.</p

Manhattan plot of common variant associations with atrial fibrillation.

<p>Manhattan plot of common variant associations with atrial fibrillation.</p

Statistical power with current sample size and α = 5x10^-7.

<p>Statistical power with current sample size and α = 5x10^-7.</p

Most significant common variants associated with atrial fibrillation.

<p>Most significant common variants associated with atrial fibrillation.</p

Assessment of variant enrichment in genes purportedly implicated in atrial fibrillation.

<p>Assessment of variant enrichment in genes purportedly implicated in atrial fibrillation.</p

Baseline characteristics of the participating studies.

<p>Baseline characteristics of the participating studies.</p